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ene (TCE), a major ground water contaminant
used in the dry cleaning industry and in
degreasing solvents.
The degree to which B. cepacia is being used
in bioremediation products is unknown; how-
ever, the species has been used extensively to
degrade ground water TCE contamination in at
least one large U.S. city. A number of
environment-friendly bioremediation products
containing only naturally occurring, nonpatho-
genic bacteria are being marketed for use in
drain opening and grease eradication systems.
Because their formulations are proprietary, it is
not known if these products contain B. cepacia;
however, franchises that distribute such totally
natural, noncorrosive, nontoxic products specifi-
cally target fast-food restaurants, photo process-
ing facilities, and hospital radiology departments.
In the United States, the biopesticidal use of
microorganisms such as B. cepacia is regulated
by the Environmental Protection Agency (EPA)
under the Federal Insecticide, Fungicide, and
Rodenticide Act; however, the use of naturally
occurring, nonpathogenic bacteria as bioremedial
agents is essentially unregulated. Only new
microorganisms (i.e., intergeneric or formed by
combining genetic material from organisms in
different genera) are regulated by EPA under the
Toxic Substances Control Act (TSCA) (2).
Ironically, TSCA regulations provide a strong
disincentive to the development of safer
microbiologic alternatives for use in
bioremediation. For example, although the
genetic elements responsible for TCE degrada-
tion by B. cepacia have been cloned, their
recombination into another nonpathogenic
bacterial host (e.g., Escherichia coli) would
constitute a new microorganism, the licensure of
which would be considered prohibitively time-
consuming and expensive by many companies.
In Canada, biopesticidal uses of microorgan-
isms are regulated by the Pest Management
Regulatory Agency of Health Canada, under the
Pest Control Products Act (PCPA); bioremedial
uses are regulated by Environment Canada
under the Canadian Environmental Protection
Act (CEPA) (3). Both naturally occurring and
genetically engineered microorganisms are
strictly controlled under these acts. However,
accurate species identification is the cornerstone
of all notification of products under the Canadian
regulations. This presents a further dilemma. At
least five genomovars (discrete species) consti-
tute what has recently been designated the
B. cepacia complex (4). Insofar as the taxonomy
of this group is poorly defined, there are no
conventional taxonomic designations to distin-
guish pathogenic from nonpathogenic species. At
present, it appears that all five B. cepacia
genomovars are capable of causing infections in
vulnerable persons (4).
Because the epidemiology of B. cepacia
complex infection in humans is incompletely
understood, the threat posed by the inclusion of
this species in biopesticides and bioremedial
products is difficult to quantify. However, we
agree with Holmes et al. that such use should be
approached with considerable caution. In a
broader context, the commercial use of B. cepacia
illustrates our incomplete understanding of
nonpathogenic bacteria and their potential to
cause human disease. Regulations governing the
use of microorganisms in industry must
constantly adapt to keep pace with the
emergence of infections due to nonpathogens and
limit risk to human health.
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Human Rabies in Israel
To the Editor: Rabies, a major zoonotic disease in
the Middle East, has two main epidemiologic
forms: urban and sylvatic. The last case of
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human rabies in Israel was in the Golan Heights
in 1971 (1). Twenty-five years later, in 1996,
rabies was reported in a 20-year-old soldier, and
then two cases were documented in 1997.
The first case-patient, a soldier in the Golan
Heights, was bitten on the lip by an unidentified
animal while sleeping. The wound was cleansed
and sutured; clinical signs started 39 days later
with high fever and headache. The patient was
admitted to an emergency room with hallucina-
tions, difficulty in swallowing, and generalized
weakness, and rabies was considered in the
differential diagnosis; 3 days later the patient
became comatose. Samples of saliva, serum, and
cerebrospinal fluid; skin biopsy tissue; and
corneal impressions were sent to the Pasteur
Institute, Paris, France. Eight days after clinical
signs developed, rabies was diagnosed by the
Kimron Institute by heminested reverse tran-
scription-polymerase chain reaction (hnRT-
PCR) on the patients saliva (2). The RT step was
performed with the specific primer 113 (5’-
GTAGGATGATATATGGG-’3 at 1013-1030), fol-
lowed by PCR with the 509 (5’-GAGAAAGA
ACTTCAAGA-’3 at 1156-1173) and 304 (5’-GAGT
CACTCGAATATGTC-’3 at 1513-1533) primers.
The hn-PCR was performed with the 509 and 105
( 5 ’ - T T C T T A T G A G T C A C T C G A A T A
TGTCTTGTTTAG-’3 at 1393-1426) primers (3).
The PCR results were confirmed by the Pasteur
Institute 3 days later, and the patient died 35
days after clinical symptoms appeared.
The second case-patient was a 7-year-old girl
admitted to the hospital unconscious. Two
months before admission, she had been
scratched while sleeping by an unidentified
animal. On the second hospital day, generalized
convulsions and gasping occurred. During the
following days, brain stem function progres-
sively deteriorated. Rabies was diagnosed by
hnRT-PCR on the saliva sample, and the
diagnosis was confirmed by the Centers for
Disease Control and Prevention (CDC). The
patient died despite supportive care.
The third case-patient, a 58-year-old man
with fever, headache, and sore throat, was
diagnosed as having pharyngitis and received an
oral antibiotic. The patient had been bitten 3
months earlier while sleeping. On admission, the
lumbar puncture, computerized tomography
scan, and electroencephalogram were normal.
On the third hospital day, he had respiratory
arrest; during orotracheal intubation, acute
laryngospasm with copious amounts of saliva-
tion occurred. Rabies was suspected, and viral
RNA in the saliva was detected by hnRT-PCR.
One day later the patient died.
We injected antemortem saliva and postmor-
tem brain tissue from these patients into
suckling mice intracerebrally. Virus was isolated
from saliva samples of case-patients 1 and 3 but
not from the sample of case-patient 2. Rabies
virus antigen in the brain tissue was confirmed
by direct immunofluorescence assay, and viral
RNA was detected by RT-PCR.
For genetic analysis, we used brain samples
from the three case-patients and from animals
that died of rabies near the location of the case-
patients to amplify and sequence a 328-bp (264
bp from the 3’ of the N gene and 64 bp of the
3’ NS-N region) fragment. On the basis of
homologic results of nucleotide sequences in the
three case-patients and in virus isolates from
animals in the same regions, we concluded that a
reservoir for rabies in foxes is responsible for
infection of all three humans.
The three human isolates were tested with a
panel of 19 anti-N protein monoclonal antibodies
(CDC, Atlanta, GA, USA) and compared with
those of rabies isolates from the geographic
vicinity of the human cases. Isolates from case-
patients 1 and 3 belonged to variant 1 (MAb C18
negative) and were similar to virus isolates from
10 foxes, one jackal, and four cattle in the same
regions. Isolates from case-patient 2 belonged to
antigenic variant 2 (MAbs C2, C7, C12, C13, C18
negative) and were similar to isolates from four
foxes, one dog, and one cow in the vicinity of the
second case-patient.
Early antemortem diagnosis of virus in an
infected human is very important. Checking for
virus in saliva eliminates the difficulty of tissue
sampling from humans with suspected cases of
rabies, and the sensitivity of hnRT-PCR makes it
the technique of choice for detecting limited
amounts of virus. Previous work showed that a
200-bp region of the N gene had only one
nucleotide difference between them (4). More-
over, two samples from a region in western
Mexico, isolated 30 years apart, were identical in
sequence (4). Incorporation of the reference
strains Pasteur and SAD B19 into our
phylogenetic tree indicated that the three human
viruses we isolated belong to lyssavirus genotype 1.
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Emerging Infections and Disease
Emergence
To the Editor: Emerging infections have been
defined as diseases whose incidence in humans
has increased within the last 2 decades or
threatens to increase in the near future (l). This
definition, with minor variations, has continued
to be used, although occasional debate erupts
over whether one disease or another is truly
emerging. Use of the term emerging has
facilitated communication about the changed
pattern of infectious diseases in recent years.
While the study of infectious organisms and
clinical training about emerging infections are
manifestly necessary, they are not a sufficient
foundation for understanding the process of
disease emergence. I would propose, specifically,
that we distinguish between emerging dis-
easesthe study of specific infections that are
changingand the study of disease emergence.
Studies of emerging infections typically rely
on disease, organismic, or syndromic ap-
proaches. Meetings on emerging infections
typically cover newly recognized or character-
ized organisms or diseases and update informa-
tion about the recognition, diagnosis, treatment,
prevention, and control of these infections. This
ongoing education is essential for practicing
clinicians, who finished their formal training
before AIDS, Lyme disease, ehrlichiosis,
Helicobacter pylori infection, cryptosporidiosis,
cyclosporiasis, and many other infections were
described. These meetings also help clinicians
learn how to fit new information into their existing
knowledge base: What is the probability that a
person with rash and fever has ehrlichiosis and
that a person with fever and pulmonary
infiltrates has hantavirus pulmonary syndrome?
By contrast, understanding the process of
disease emergence involves studying the origins
and ecology of emerging infections. Many
disciplines relevant to disease emergence lie
outside traditional infectious disease training
and research and include evolutionary biology,
demography, population dynamics, ecology,
vector biology, climatology, epidemiology, genet-
ics, veterinary medicine, and behavioral sciences
(2). Infectious diseases of animals and plants
have both a direct and indirect impact on human
health. The study of infectious diseases in other
species may provide important insights into
understanding the process of disease emergence
in humans. The study is also relevant to
understanding the species-to-species spread of
organisms.
Tools used to study and understand disease
emergence include mathematical modeling,
geographic information systems, remote sens-
ing, molecular methods to study the genetic
relatedness of organisms, and molecular phylog-
eny. Paleobiology, paleoecology, and studies that
allow the reconstruction of past events may help
inform future research and policy.
A major challenge is to reach people with
relevant skills, knowledge, and experience and
develop a coherent framework to advance the
understanding of the process of disease
emergence. No one institution, organization, or
country can itself prevent or manage emerging
infectious diseases.
In the study of emerging infections we focus
on the organism, the patient, and the human
population. The study of disease emergence must
be at the systems level and must look at
ecosystems, evolutionary biology, and popula-
tions of parasites and hosts, whatever their
species. A primary goal should be to identify
conditions or combinations or sequences of
events that herald a changed pattern of infections
so that preventive strategies can be used.
